ISB-1442 is under clinical development by Ichnos Sciences and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISB-1442’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ISB-1442 overview
See Also:
Ichnos Sciences overview
Ichnos Sciences is a bio pharmaceutical manufacturing company. The company is engaged in developing therapies for treating oncology and autoimmune disease. It’s technology portfolio includes BEAT (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform which uses a novel method for engineering bispecific antibodies that may treat cancers and ISB 830 is designed to block the key immune system activation factor to treat a variety of illnesses and provides an entirely novel method of action for the treatment of autoimmune disease. Ichnos Sciences is headquartered in New York, the US.
For a complete picture of ISB-1442’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
